Poolbeg Pharma's POLB 001 Takes Center Stage in £3.4 Million CRS Prevention Research Programme
核心洞察
Poolbeg Pharma (搜索)'s POLB 001 trial will be central to the RISE programme, a £3.4 million MRC-funded initiative led by The University of Manchester and The Christie NHS Foundation Trust to address cytokine release syndrome (搜索) in cancer (搜索) immunotherapy.
The p38-MAP-kinase (搜索) inhibitor POLB 001 aims to prevent CRS, which affects 50-90% of patients receiving bispecific antibody and CAR-T cell therapies, potentially making these breakthrough treatments safer and more accessible.
Poolbeg serves as lead business partner alongside Johnson & Johnson, which will provide the bispecific antibody teclistamab for the Phase IIa TOPICAL trial, with results expected in summer 2026.
Poolbeg Pharma (搜索)'s investigational drug POLB 001 has been selected as the centerpiece of a groundbreaking £3.4 million research programme aimed at addressing one of cancer (搜索) immunotherapy's most significant safety challenges: cytokine release syndrome (搜索) (CRS). The clinical-stage biopharmaceutical company will serve as lead business partner in the RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies) programme, working alongside Johnson & Johnson and other industry partners.
The programme, led by The University of Manchester and The Christie NHS Foundation Trust, is supported by a Medical Research Council Prosperity Partnership grant and represents part of a broader £9 million public sector investment in advanced therapy safety research. Central to RISE will be Poolbeg's Phase IIa TOPICAL trial, which will evaluate POLB 001's potential to prevent CRS in patients receiving cancer (搜索) immunotherapies.
Addressing a Critical Safety Bottleneck
CRS occurs in approximately 50-90% of patients receiving bispecific antibody and CAR-T cell therapies, creating a significant barrier to the broader availability and uptake of these breakthrough cancer (搜索) treatments. The syndrome represents a serious adverse effect that, along with high treatment costs, has limited the widespread use of these potentially life-saving immunotherapies.
POLB 001, a p38-MAP-kinase (搜索) inhibitor, is specifically designed to prevent CRS before it occurs, potentially making bispecific antibody and CAR-T cell therapies safer with fewer side effects. The drug's mechanism targets the inflammatory pathway that leads to excessive cytokine release, offering a proactive approach to managing this treatment-limiting toxicity.
Industry-Academic Collaboration
Johnson & Johnson will provide teclistamab, an approved BCMA (搜索) × CD3 (搜索) bispecific antibody, for the TOPICAL trial. The collaboration exemplifies how academic-industry partnerships can accelerate discovery and ensure advanced therapies are delivered safely and responsibly.
"Advanced immunotherapies are the future of cancer (搜索) treatment but can come with some severe adverse effects, such as CRS," said Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma (搜索). "This programme will deepen the understanding of CRS and could be beneficial for POLB 001, as we seek to bring its potential benefits to patients."
Dr Jonathan Lim, Clinical Senior Lecturer and Honorary Consultant Medical Oncologist in Advanced Immunotherapy and Cell Therapy at The Christie, emphasized the programme's multidisciplinary approach: "RISE harnesses Manchester's multidisciplinary strengths to explore the biology behind both the power and the risks of modern cancer (搜索) immunotherapies."
Broader Research Implications
Beyond the TOPICAL trial, the RISE programme will collect clinical data from patients treated with bispecific antibodies and CAR-T cell therapies to further evaluate POLB 001's potential in preventing cancer (搜索) immunotherapy-induced CRS. This expanded research scope reflects the growing recognition of the unmet medical need in managing CRS and other serious adverse effects.
The programme aligns with The Christie's ambition to position the UK as a global leader in research focused on the safe delivery of cancer (搜索) immunotherapies. Dr Glenn Wells, MRC Deputy Executive Chair, noted that the research is "critical to improving how gene, cell-based, and nucleic acid-dependent therapies are developed for conditions such as cancers and rare genetic disorders."
Timeline and Financial Impact
Results from the POLB 001 TOPICAL trial are anticipated in summer 2026, with the RISE programme not expected to impact this timeline. Poolbeg's participation in the programme will not affect the company's cash runway into 2027, providing financial stability as the research progresses.
The initiative represents a significant step toward making advanced cancer (搜索) immunotherapies more accessible by addressing their primary safety limitation, potentially expanding treatment options for patients with various cancer types.